Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 549101, 10 pages
http://dx.doi.org/10.1155/2010/549101
Review Article

AMPK-Dependent Metabolic Regulation by PPAR Agonists

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea

Received 22 April 2010; Accepted 25 June 2010

Academic Editor: Howard Glauert

Copyright © 2010 Woo Hyung Lee and Sang Geon Kim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Ahmed, O. Ziouzenkova, J. Brown et al., “PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?” Journal of Internal Medicine, vol. 262, no. 2, pp. 184–198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Diradourian, J. Girard, and J.-P. Pégorier, “Phosphorylation of PPARs: from molecular characterization to physiological relevance,” Biochimie, vol. 87, no. 1, pp. 33–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Chanda, C. H. Lee, Y.-H. Kim et al., “Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner,” Hepatology, vol. 50, no. 3, pp. 880–892, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Liangpunsakul, S.-E. Wou, K. D. Wineinger et al., “Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase,” Archives of Biochemistry and Biophysics, vol. 485, no. 1, pp. 10–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. G. D. Fryer, A. Parbu-Patel, and D. Carling, “The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways,” Journal of Biological Chemistry, vol. 277, no. 28, pp. 25226–25232, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. K. Saha, P. R. Avilucea, J.-M. Ye, M. M. Assifi, E. W. Kraegen, and N. B. Ruderman, “Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo,” Biochemical and Biophysical Research Communications, vol. 314, no. 2, pp. 580–585, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. N. K. LeBrasseur, M. Kelly, T.-S. Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 1, pp. E175–E181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Zoete, A. Grosdidier, and O. Michielin, “Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 915–925, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Gianní, A. Tarrade, E. A. Nigro, E. Garattini, and C. Rochette-Egly, “The AF-1 and AF-2 domains of RARγ2 and RXRα cooperate for triggering the transactivation and the degradation of RARγ2/RXRα heterodimers,” Journal of Biological Chemistry, vol. 278, no. 36, pp. 34458–34466, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Yoon, “The role of PPARα in lipid metabolism and obesity: focusing on the effects of estrogen on PPARα actions,” Pharmacological Research, vol. 60, no. 3, pp. 151–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Costet, C. Legendre, J. Moré, A. Edgar, P. Galtier, and T. Pineau, “Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis,” Journal of Biological Chemistry, vol. 273, no. 45, pp. 29577–29585, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Barberá, A. Schlüter, N. Pedraza, R. Iglesias, F. Villarroya, and M. Giralt, “Peroxisome proliferator-activated receptor α activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell,” Journal of Biological Chemistry, vol. 276, no. 2, pp. 1486–1493, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Nakatani, N. Tsuboyama-Kasaoka, M. Takahashi, S. Miura, and O. Ezaki, “Mechanism for peroxisome proliferator-activated receptor-α activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes,” Journal of Biological Chemistry, vol. 277, no. 11, pp. 9562–9569, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Brun, M. C. Carmona, T. Mampel et al., “Activators of peroxisome proliferator-activated receptor-α induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth,” Diabetes, vol. 48, no. 6, pp. 1217–1222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPARδ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. T. E. Johnson, M. K. Holloway, R. Vogel et al., “Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors,” Journal of Steroid Biochemistry and Molecular Biology, vol. 63, no. 1–3, pp. 1–8, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Chawla, C.-H. Lee, Y. Barak et al., “PPARδ is a very low-density lipoprotein sensor in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1268–1273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. Y.-X. Wang, C.-L. Zhang, R. T. Yu et al., “Regulation of muscle fiber type and running endurance by PPARδ,” PLoS Biology, vol. 2, no. 10, article e294, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. V. A. Narkar, M. Downes, R. T. Yu et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell, vol. 134, no. 3, pp. 405–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Chawla, W. A. Boisvert, C.-H. Lee et al., “A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis,” Molecular Cell, vol. 7, no. 1, pp. 161–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Kubota, Y. Terauchi, H. Miki et al., “PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Sugii, P. Olson, D. D. Sears et al., “PPARγ activation in adipocytes is sufficient for systemic insulin sensitization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 52, pp. 22504–22509, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-G. Jiang, C. Johnson, and R. Zarnegar, “Peroxisome proliferator-activated receptor γ-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element,” Journal of Biological Chemistry, vol. 276, no. 27, pp. 25049–25056, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Han, D. P. Hajjar, X. Zhou, A. M. Gotto Jr., and A. C. Nicholson, “Regulation of peroxisome proliferator-activated receptor-γ-mediated gene expression a new mechanism of action for high density lipoprotein,” Journal of Biological Chemistry, vol. 277, no. 26, pp. 23582–23586, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. D. K. Coletta, A. Sriwijitkamol, E. Wajcberg et al., “Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial,” Diabetologia, vol. 52, no. 4, pp. 723–732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. C. Towler and D. G. Hardie, “AMP-activated protein kinase in metabolic control and insulin signaling,” Circulation Research, vol. 100, no. 3, pp. 328–341, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Lage, C. Diéguez, A. Vidal-Puig, and M. López, “AMPK: a metabolic gauge regulating whole-body energy homeostasis,” Trends in Molecular Medicine, vol. 14, no. 12, pp. 539–549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Woods, S. R. Johnstone, K. Dickerson et al., “LKB1 is the upstream kinase in the AMP-activated protein kinase cascade,” Current Biology, vol. 13, no. 22, pp. 2004–2008, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. A. Hawley, D. A. Pan, K. J. Mustard et al., “Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase,” Cell Metabolism, vol. 2, no. 1, pp. 9–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Momcilovic, S.-P. Hong, and M. Carlson, “Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro,” Journal of Biological Chemistry, vol. 281, no. 35, pp. 25336–25343, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. D. R. Alessi, K. Sakamoto, and J. R. Bayascas, “LKB1-dependent signaling pathways,” Annual Review of Biochemistry, vol. 75, pp. 137–163, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Xie, Y. Dong, R. Scholz, D. Neumann, and M.-H. Zou, “Phosphorylation of LKB1 at serine 428 by protein kinase C-ζ is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells,” Circulation, vol. 117, no. 7, pp. 952–962, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. L. Hurley, K. A. Anderson, J. M. Franzone, B. E. Kemp, A. R. Means, and L. A. Witters, “The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases,” Journal of Biological Chemistry, vol. 280, no. 32, pp. 29060–29066, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Bugianesi, A. J. McCullough, and G. Marchesini, “Insulin resistance: a metabolic pathway to chronic liver disease,” Hepatology, vol. 42, no. 5, pp. 987–1000, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Inoki, T. Zhu, and K.-L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-S. Park, H. Zhao, R. A. Mueller, and Z. Xu, “Bradykinin prevents reperfusion injury bytargeting mitochondrial permeability transition pore through glycogen synthase kinase 3β,” Journal of Molecular and Cellular Cardiology, vol. 40, no. 5, pp. 708–716, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. S. M. Shin, I. J. Cho, and S. G. Kim, “Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3β inhibition downstream of poly(ADP-ribose) polymerase-LKB1 pathway,” Molecular Pharmacology, vol. 76, no. 4, pp. 884–895, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Motoshima, B. J. Goldstein, M. Igata, and E. Araki, “AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer,” Journal of Physiology, vol. 574, no. 1, pp. 63–71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Rattan, S. Giri, A. K. Singh, and I. Singh, “5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 39582–39593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. B. B. Zhang, G. Zhou, and C. Li, “AMPK: an emerging drug target for diabetes and the metabolic syndrome,” Cell Metabolism, vol. 9, no. 5, pp. 407–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. E. J. Kurth-Kraczek, M. F. Hirshman, L. J. Goodyear, and W. W. Winder, “5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle,” Diabetes, vol. 48, no. 8, pp. 1667–1671, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. S. H. Hwahng, S. H. Ki, E. J. Bae, H. E. Kim, and S. G. Kim, “Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones,” Hepatology, vol. 49, no. 6, pp. 1913–1925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Carling, P. R. Clarke, V. A. Zammit, and D. G. Hardie, “Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities,” European Journal of Biochemistry, vol. 186, no. 1-2, pp. 129–136, 1989. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Fisslthaler and I. Fleming, “Activation and signaling by the AMP-activated protein kinase in endothelial cells,” Circulation Research, vol. 105, no. 2, pp. 114–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Nagata and Y. Hirata, “The role of AMP-activated protein kinase in the cardiovascular system,” Hypertension Research, vol. 33, no. 1, pp. 22–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Gutierrez, S. W. Ballinger, V. M. Darley-Usmar, and A. Landar, “Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells,” Circulation Research, vol. 99, no. 9, pp. 924–932, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. J. C. Choy, D. J. Granville, D. W. C. Hunt, and B. M. McManus, “Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 9, pp. 1673–1690, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Ceolotto, A. Gallo, I. Papparella et al., “Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2627–2633, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Fujisawa, T. Nishikawa, D. Kukidome et al., “TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis,” Biochemical and Biophysical Research Communications, vol. 379, no. 1, pp. 43–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Nagata, M. Mogi, and K. Walsh, “AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 31000–31006, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Bogardus, S. Lillioja, D. M. Mott, C. Hollenbeck, and G. Reaven, “Relationship between degree of obesity and in vivo insulin action in man,” American journal of physiology, vol. 248, no. 3, part 1, pp. E286–E291, 1985. View at Google Scholar · View at Scopus
  56. M. Okazaki, Y. Iwasaki, M. Nishiyama et al., “PPARβ/δ regulates the human SIRT1 gene transcription via Sp1,” Endocrine Journal, vol. 57, no. 5, pp. 403–413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. Z. Shen, X. Liang, C. Q. Rogers, D. Rideout, and M. You, “Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 298, no. 3, pp. G364–G374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Qureshi and G. A. Abrams, “Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 13, no. 26, pp. 3540–3553, 2007. View at Google Scholar · View at Scopus
  59. X. Wang, L. Zhou, L. Shao et al., “Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells,” Life Sciences, vol. 81, no. 2, pp. 160–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Lamontagne, É. Pepin, M.-L. Peyot et al., “Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic β-cell at submaximal glucose concentrations,” Endocrinology, vol. 150, no. 8, pp. 3465–3474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Zhang, D. Dey, R. Bränstrom et al., “BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP- Activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose- Stimulated insulin secretion in a PI3K-dependent manner,” American Journal of Physiology - Cell Physiology, vol. 296, no. 2, pp. C346–C354, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. T.-J. Chang, W.-P. Chen, C. Yang et al., “Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the KATP channel and insulin secretion in rats,” Diabetologia, vol. 52, no. 6, pp. 1112–1121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J.-M. Ye, N. Dzamko, A. J. Hoy, M. A. Iglesias, B. Kemp, and E. Kraegen, “Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats,” Diabetes, vol. 55, no. 10, pp. 2797–2804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Xiao, G. Su, S. N. Brown, L. Chen, J. Ren, and P. Zhao, “Peroxisome proliferator-activated receptors γ and α agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase,” Journal of Nutritional Biochemistry, vol. 21, no. 7, pp. 621–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Dimopoulos, M. Watson, C. Green, and H. S. Hundal, “The PPARδ agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells,” FEBS Letters, vol. 581, no. 24, pp. 4743–4748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. V. Ratziu, F. Charlotte, C. Bernhardt et al., “Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial,” Hepatology, vol. 51, no. 2, pp. 445–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Gastaldelli, S. A. Harrison, R. Belfort-Aguilar et al., “Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis,” Hepatology, vol. 50, no. 4, pp. 1087–1093, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Krishnan, M. Suter, R. Windak et al., “Activation of a HIF1α-PPARγ axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy,” Cell Metabolism, vol. 9, no. 6, pp. 512–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Murakami, R. Murakami, F. Kambe et al., “Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC,” Biochemical and Biophysical Research Communications, vol. 341, no. 4, pp. 973–978, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Okayasu, A. Tomizawa, K. Suzuki, K.-I. Manaka, and Y. Hattori, “PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation,” Life Sciences, vol. 82, no. 15-16, pp. 884–891, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. G. Boyle, P. J. Logan, M.-A. Ewart et al., “Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase,” Journal of Biological Chemistry, vol. 283, no. 17, pp. 11210–11217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. S. H. Caldwell, E. E. Hespenheide, J. A. Redick, J. C. Iezzoni, E. H. Battle, and B. L. Sheppard, “A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 96, no. 2, pp. 519–525, 2001. View at Publisher · View at Google Scholar · View at Scopus